/MDNA.TO

MDNA.TO Stock - Medicenna Therapeutics Corp.

Q: What is the analyst price target for MDNA.TO?

Analyst price target information is not currently available for MDNA.TO.

Q: What is MDNA.TO's market cap?

Market capitalization information is not currently available for MDNA.TO.

Healthcare|Biotechnology|TSX

$0.99-1.98%

$0.02 (-1.98%) • Dec 22

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $1.09

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for MDNA.TO

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

FY2022

FY2023

FY2024

FY2025

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.88

52W High$1.98

52W Low$0.78

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	$-55,000	$-5,000	$-5,000	$-38,000	$-40,000
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-21,631,000	$-19,663,000	$-21,643,000	$-22,300,000	$-17,187,000
Net Income	$-11,805,000	$-25,466,000	$1.55M	$-22,646,000	$-17,183,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-0.15	$-0.37	$0.02	$-0.42	$-0.35

Company Overview

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

Visit Website

Earnings History & Surprises

MDNA.TO

Beat Rate

56%

Last 16 quarters

Avg Surprise

+6.2%

EPS vs Estimate

Beats / Misses

9/4

3 met exactly

Latest EPS

$-0.06

Q4 2025

EPS Surprise History

Q1 24

0.0%

$-0.07vs$-0.07

Q2 24

-237.7%

$-0.20vs$-0.06

Q3 24

+16.7%

$-0.05vs$-0.06

Q4 24

+16.7%

$-0.05vs$-0.06

Q1 25

0.0%

$-0.07vs$-0.07

Q1 25

No data

Q3 25

+133.3%

$0.02vs$-0.06

Q4 25

-9.8%

$-0.06vs$-0.05

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Feb 12, 2026	—	—	—	—
Q4 2025	Nov 12, 2025	$-0.05	$-0.06	-9.8%	✗ MISS
Q3 2025	Jul 29, 2025	$-0.06	$0.02	+133.3%	✓ BEAT
Q1 2025	Mar 31, 2025	—	$0.02	—	—
Q1 2025	Feb 12, 2025	$-0.07	$-0.07	0.0%	= MET
Q4 2024	Nov 14, 2024	$-0.06	$-0.05	+16.7%	✓ BEAT
Q3 2024	Jul 31, 2024	$-0.06	$-0.05	+16.7%	✓ BEAT
Q2 2024	Apr 16, 2024	$-0.06	$-0.20	-237.7%	✗ MISS
Q1 2024	Feb 14, 2024	$-0.07	$-0.07	0.0%	= MET
Q4 2023	Nov 14, 2023	$-0.07	$-0.05	+28.6%	✓ BEAT
Q3 2023	Jul 28, 2023	$-0.06	$-0.04	+33.3%	✓ BEAT
Q1 2023	Mar 31, 2023	—	$-0.06	—	—
Q1 2023	Feb 7, 2023	$-0.09	$-0.02	+77.8%	✓ BEAT
Q4 2022	Nov 4, 2022	$-0.07	$-0.04	+42.9%	✓ BEAT
Q3 2022	Aug 15, 2022	$-0.08	$-0.07	+12.5%	✓ BEAT
Q1 2022	Mar 31, 2022	—	$-0.06	—	—
Q1 2022	Feb 9, 2022	$-0.13	$-0.09	+30.8%	✓ BEAT
Q4 2021	Nov 12, 2021	$-0.12	$-0.15	-25.0%	✗ MISS
Q3 2021	Aug 13, 2021	$-0.10	$-0.12	-20.0%	✗ MISS
Q2 2021	May 28, 2021	$-0.11	$-0.11	0.0%	= MET

Frequently Asked Questions about MDNA.TO

What is MDNA.TO's current stock price?

Medicenna Therapeutics Corp. (MDNA.TO) is currently trading at $0.99 per share. The stock has moved -1.98% today.

What is the analyst price target for MDNA.TO?

No analyst price targets are currently available for this stock.

What sector is Medicenna Therapeutics Corp. in?

Medicenna Therapeutics Corp. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the TSX exchange.

What is MDNA.TO's market cap?

Medicenna Therapeutics Corp. has a market capitalization of $0.07 billion, making it a small-cap company.

Does MDNA.TO pay dividends?

No, Medicenna Therapeutics Corp. does not currently pay a dividend to shareholders.